Almandoz explained that while GLP-1 receptor agonism alone delivers meaningful benefits in appetite regulation, satiety, glycemic control, and cardiorenal and liver outcomes, the addition of glucagon receptor agonism introduces a distinct and complementary layer of biology that goes beyond weight loss alone to address the metabolic drivers most closely linked to insulin resistance, cardiometabolic risk, and MASH progression.
Jaime Almandoz characterized the historical management of metabolic disease as paradoxically siloed given how biologically integrated these conditions are, noting that a patient may have their obesity managed by one clinician, their diabetes by another, their cardiovascular disease by a third, and their liver disease, if addressed at all, evaluated in yet another separate setting, while the patient is experiencing all of these as one interconnected metabolic condition, creating fragmentation that delays diagnosis, duplicates effort, and leaves critical windows for intervention unaddressed.
Quantitative hepatitis B surface antigen testing is emerging as a critical tool for identifying which patients may respond best to next-generation therapies. This episode reviews new guideline recommendations and finite-duration therapy conversations.
Unlike hepatitis C, chronic hepatitis B does not always progress through classic fibrosis, making liver cancer possible without significant liver damage. This episode reviews how genomic integration drives that risk and how monitoring should adapt.
JAK inhibitors mark a genuine shift in vitiligo care, offering stabilization before repigmentation and color that matches native skin tone. Dr. Desai and Dr. Lal weigh their promise against the patience and compliance they demand.
From corticosteroids and calcineurin inhibitors to phototherapy, oral supplements, and emerging JAK inhibitors, Dr. Rosmarin walks through a treatment landscape defined by combination therapy rather than any single modality working alone.
Almandoz framed obesity, type 2 diabetes, cardiovascular disease, and MASH not as separate conditions but as different manifestations of the same underlying metabolic dysfunction, making MASH not merely a liver problem but a signal of broader cardiometabolic burden that demands comprehensive attention.
Noureddin drew on the prior Phase 2 survodutide data published in the New England Journal of Medicine, which demonstrated improvements in steatohepatitis histology and significant fibrosis reduction to contextualize the SYNCHRONIZE-1 findings, noting that MRI-based proton density fat fraction reduction has been shown to correlate with histologic improvement in steatohepatitis and fibrosis, suggesting the magnitude of liver fat reduction observed in SYNCHRONIZE-1 is a predictive surrogate for the histologic endpoints being evaluated in the ongoing Phase 3 LIVERAGE and LIVERAGE Cirrhosis trials.
Chronic hepatitis B remains highly prevalent yet chronically underdiagnosed in the United States. This episode reviews global and domestic epidemiology, new universal screening guidance, and a health-system model built to close the gap.
Chronic hepatitis B is often framed purely as a viral disease, but immune suppression from surface antigen excess is central to how it behaves. This episode examines why targeting that immune dimension is essential to curing it.
A recent JAMA Dermatology analysis refines mild-moderate-severe cutoffs for vitiligo, but Dr. Desai and Dr. Lal argue that psychosocial burden, anatomic site, and cultural context can make even limited disease profoundly severe for patients.
Halting progression early is more achievable than reversing it. Dr. Rosmarin details how oral steroids control active disease while payer barriers persist for later-line options, and Jason explains how benefit design and step therapy shape access.
The SYNCHRONIZE-1 trial was a Phase III double-blind study in which patients with elevated BMI were randomized in a one-to-one-to-one ratio to placebo, 3.6 mg, or 6.6 mg of survodutide alongside lifestyle counseling, with the primary endpoint of at least 5% weight loss at week 76.
Noureddin framed the emergence of dual GLP-1/glucagon receptor agonism as a significant development, placing it alongside artificial intelligence as a transformative force in medicine, noting that while GLP-1 receptor agonists have already improved the management of metabolic syndrome and generated robust data across obesity and cardiovascular outcomes, the bar has now moved higher, with tolerability, injection frequency, oral versus injectable delivery, and liver-specific activity all emerging as key differentiators among the next generation of incretin-based therapies.
Noureddin acknowledged the extraordinary challenge facing primary care physicians who are tasked with managing a patient holistically across rapidly evolving fields and expressed genuine appreciation for the breadth of responsibility they carry.
Body surface area offers a simple starting point for gauging vitiligo severity, but the panel argues that phenotype markers, anatomic location, and disease activity carry more weight in shaping treatment urgency than surface area alone.
Noureddin outlined the striking epidemiological burden of MASLD and MASH in patients with obesity, with prevalence climbing dramatically with increasing BMI, reaching up to 90% in patients with a BMI of 40 or higher, and affecting approximately 60% of individuals with type 2 diabetes.
Angela Lamb discussed the switching data from the LEVEL UP trial, noting that patients who had not met treatment goals on dupilumab and switched to upadacitinib were able to achieve meaningful improvements, reinforcing the message to patients that failure on one biologic does not preclude success with another.
Vitiligo's clinical course splits into segmental and non-segmental presentations, each carrying a distinct prognosis. Dr. Rosmarin explains how disease activity, not just extent, determines whether a patient needs urgent intervention or watchful monitoring.
Noureddin framed MASH as one that should not be viewed in isolation by hepatologists or any other specialist, but rather understood as part of a broader cardio-liver-renal metabolic syndrome that demands comprehensive, multidisciplinary management, noting that even lean individuals with elevated visceral fat and insulin resistance can develop MASLD, and that the risk increases substantially with higher BMI and the presence of type 2 diabetes, which is strongly associated with both higher MASLD prevalence and greater rates of advanced fibrosis and cirrhosis.
Angela Lamb discussed how advanced therapy selection — spanning interleukin-4 (IL-4), IL-13, and IL-31 inhibitors as well as oral Janus kinase (JAK) inhibitors — is guided by patient phenotype, age-based restrictions, disease severity, and whether the presentation is more itch-dominant or body surface area (BSA)-dominant rather than a one-size-fits-all approach.
Nadege Gunn examined the stark economic contrast between the cost of early pharmacologic intervention in MASH and the astronomical healthcare utilization associated with late-stage liver disease, arguing that the cost of allowing MASH to progress unchecked to the point of hepatic decompensation, liver transplantation, or hepatocellular carcinoma far exceeds the investment required to treat the disease earlier with therapies capable of reversing fibrosis and resolving MASH before those devastating endpoints are reached.
Experts outline evolving EP-NEC care: smarter combo therapies, DLL3 targets, precise pathology, and why early clinical trials matter.
Gunn described her reaction to the SYNCHRONIZE-1 liver fat reduction data as genuinely compelling from a hepatology perspective, noting a reduction of up to 63% represents a level of hepatic fat clearance that could meaningfully transform the disease trajectory for patients, with the data also demonstrating reductions in non-invasive markers of fibrosis such as ELF and Pro-C3, adding further weight to the possibility that this combination could address not just fat accumulation but the fibrotic progression that drives the most serious liver-related morbidity.
Angela Lamb discussed how the lack of robust head-to-head comparative data across interleukin-targeting biologics contributes to biologic cycling, noting that without clear guidance on which agent best matches a given patient's immunologic drivers, clinician decision-making often relies on phenotype and clinical experience rather than predictive data.
Gunn explained the scientific rationale for combining GLP-1 and glucagon receptor agonism in the context of MASH, noting that the liver contains glucagon receptors, making the combination a compelling strategy for achieving more direct hepatic targeting than GLP-1 receptor agonism alone can provide.
This episode, titled ‘Emerging Data and the Future Treatment Landscape in Extrapulmonary Neuroendocrine Carcinoma: Novel Therapies, Algorithms, and Combination Strategies,’ featured panelists discussing the following critical questions
Learn how tumor and liquid biopsy biomarker tests are ordered, why results take weeks, and how insurance rules can delay cancer treatment.
This episode, titled 'Risk Stratification and Weight Loss as Therapy: A Hepatologist's Framework for Managing MASH Progression,' features Nadege Gunn, MD discussing the following critical questions: 1. How do you risk-stratify your patients, and what clinical or metabolic factors most reliably predict progression? 2. What does the literature tell us about the relationship between meaningful weight loss and fibrosis regression, and how does that inform your thinking about weight-loss therapy as a hepatic intervention?
In 'Screening MASH Upstream: Building a Practical, Scalable Algorithm for the Real World,’ Nadege Gunn, MD delves into the following critical question: 1. There is growing interest in screening for MASH further upstream. What would a practical, scalable screening algorithm look like in your view, and what are the limitations of that approach?
